Pharmaceuticals, Biotechnology and Life Sciences
Oxford Pharmascience’s interim PK study showed that the technolology modifications can not only make OXPzero Ibuprofen bioequivalent to OTC Nurofen, but also potentially faster acting, the drugmaker said in an update on OXPzero Ibuprofen clinical program, for which on January 17, it kicked off dosing healthy patients in the first phase of the study.
US Food and Drug Administration (FDA) has accepted Novartis’s supplemental New Drug Application (sNDA) for filing, and granted Priority Review for the expanded use of Zykadia (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
PureTech Health has named new Chief Medical Officer to see all clinical operations across its pipeline and will focus on pushing chances that have most potential for patients.
PMV Pharmaceuticals, Inc., a cancer focused developer of p53-targeted small molecule drugs, has completed a Series B financing round bagging $74 million.
BD said on Wednesday that its BD Veritor System Flu A+B, a digital immunoassay for the rapid detection of influenza, meets the new Food and Drug Administration’s (FDA’s) performance requirements.
Superbug bacteria found in people, animals and food across the European Union pose an “alarming” threat to public and animal health having evolved to resist widely used antibiotics, disease and safety experts warned on Wednesday.
Syros scientists discovered alterations in regulatory regions of the genome in tumor-associated macrophages in a subset of patient tissues, the company said on Tuesday. Because these alterations are unique to the immunosuppressive state, they could point to genes critical for driving immunosuppression in the tumor microenvironment, as well as potential drug targets to reactivate the immune system to fight cancer.
A UK-based private clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) for the treatment of chronic inflammatory gastrointestinal (GI) and ocular diseases, has triggered the phase 1/2a proof of concept study in the US of TOP1630 ophthalmic solution for the treatment of the dry eye syndrome.
Verona Pharma has made an important step in the phase two clinical trial for its candidate RPL554, used for chronic obstructive pulmonary disease (COPD). Namely, the first patient has been dosed testing RPL544 as an add-on therapy to tiotropium, Spiriva.
Bayer has reported net income of €4,531 million which is 10.2% increase comparing to 2015 (€4,110 million). The company reported earnings growth in pharmaceutical activities, while other activities remain steady.